The Senate Attacks on Pharma Put the Industry in Jeopardy and Consumers at Risk
Singling out an industry segment won’t solve the underlying problem of healthcare costs.
Navigating Opportunities and Challenges in the GLP-1 Drug Gold Rush
GLP-1 agonists are transforming the weight loss market. Experts weighed in on the changes they’re seeing, speaking in a panel discussion during the MedCity News INVEST Conference in Chicago.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss
Novo Nordisk reported its weight loss pill amycretin led to greater weight loss measured at 12 weeks compared to clinical trial results for its blockbuster obesity drug Wegovy. But these results are from a small Phase 1 study and more testing is needed.
Novo Nordisk Plans €2B Site Expansion as GLP-1 Drug Demand Grows
Novo Nordisk's planned expansion will more than double the footprint of its France production site, bringing new capacity for manfacturing GLP-1 drugs for metabolic conditions. The location is already one of the company’s largest for making diabetes products.
Report: Weight Loss Drugs Cost Significantly More for Americans than Peer Countries
A new KFF analysis compared list prices for Ozempic, Wegovy, Rybelsus and Mounjaro. It found that the U.S. has much higher list prices for these drugs than other peer countries while also having the highest rate of obesity.
Novo Nordisk’s Wegovy Posts Trial Data Supporting the Drug as Way to Lower Heart Risks
Novo Nordisk weight-loss drug Wegovy reduced the risk of major cardiovascular events by 20% in a large clinical trial. The company said the results support expanding the drug’s label, but the looming question is whether the data will persuade payers to cover the pricey chronic therapy.
The Impact Brands: Empowering Wellness Through Natural and Holistic Solutions
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Coalition Applauds Reintroduction of Obesity Treatment Bill, Urges Passage
The Treat and Reduce Obesity Act would expand Medicare coverage for obesity screenings, treatments and therapies like anti-obesity medications. The Health Equity Coalition for Chronic Disease came out in favor of the bill and asked for swift passage.
LifeMD Launches GLP-1 Weight Management Program
Through LifeMD's new weight management program, consumers can gain access to GLP-1 prescriptions like Ozempic and Wegovy, clinical support, lab testing, education and more.